Blood-based gene expression signature associated with metastatic castrate-resistant prostate cancer patient response to abiraterone plus prednisone or enzalutamide.

Naomi B HaasMichael J LaRiviereThomas H BuckinghamYauheniya CherkasKarl Calara-NielsenBrad FoulkJaymala PatelSteven GrossDenis SmirnovDavid J VaughnRavi AmaravadiKathryn E WellenSamantha L SavitchKrishna J MajmundarTaylor A BlackStephanie S YeeMiaoling HeEun Jeong MinQi LongJeremy O JonesSumanta K PalErica L Carpenter

Published in: Prostate cancer and prostatic diseases (2020)

If validated in a larger prospective study, this test may predict patients most likely to benefit from second-generation antiandrogen therapy.

Keyphrases

prostate cancer
gene expression
end stage renal disease
ejection fraction
newly diagnosed
radical prostatectomy
squamous cell carcinoma
small cell lung cancer
peritoneal dialysis
dna methylation
prognostic factors
case report
stem cells
patient reported outcomes
mesenchymal stem cells